Lupin’s - US subsidiary - Lupin Pharmaceuticals, Inc. (LPI) has launched its generic Fenofibric Acid Delayed-Release Capsules 45 mg and 135 mg. The company had earlier received final approval from the USFDA for the same. Trilipix Delayed-Release Capsules 45 mg & 135 mg strengths had annual US sales of approximately $449.5 million, as per IMS MAT Sep, 2013.
Lupin’s Fenofibric Acid Delayed-Release Capsules 45 mg and 135 mg are the generic equivalent of AbbVie Inc.’s Trilipix Delayed-Release Capsules 45 mg & 135 mg strengths are indicated as co-administration therapy with statins for the treatment of mixed dyslipidemia, treatment of severe hypertriglyceridemia and primary hypercholesterolemia or mixed dyslipidemia.
Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs globally.
